Sunita Singh
Psychiatry · Allen, TXNPI 1689715302
Payments from drug & device makers
Across 247 payments — averaging $16.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$734
- Takeda Pharmaceuticals U.S.A., Inc.$560
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$357
- Tris Pharma Inc$331
- Sunovion Pharmaceuticals Inc.$322
- Lundbeck LLC$207
- plus $1K from 19 others
What the payments were for
- Food & beverage$3,93499%
- Education$491%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 46 | $734 |
| Takeda Pharmaceuticals U.S.A., Inc. | 41 | $560 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 21 | $357 |
| Tris Pharma Inc | 20 | $331 |
| Sunovion Pharmaceuticals Inc. | 18 | $322 |
| Lundbeck LLC | 12 | $207 |
| Ironshore Pharmaceuticals Inc. | 9 | $178 |
| Johnson & Johnson | 11 | $175 |
| Shire North American Group Inc | 11 | $164 |
| Supernus Pharmaceuticals, Inc. | 8 | $146 |
| Vanda Pharmaceuticals Inc. | 7 | $118 |
| Corium, LLC | 7 | $107 |
| Axsome Therapeutics, Inc. | 5 | $91 |
| Bausch Health US, LLC | 6 | $88 |
| Otsuka America Pharmaceutical, Inc. | 4 | $68 |
| Merck | 4 | $67 |
| Adlon Therapeutics L.p. | 4 | $66 |
| Neos Therapeutics, LP | 3 | $41 |
| Neuronetics, Inc. | 2 | $27 |
| Avanir Pharmaceuticals, Inc. | 2 | $26 |
| Arbor Pharmaceuticals, Inc. | 2 | $24 |
| Sage Therapeutics, LLC | 1 | $24 |
| Noven Therapeutics, LLC | 1 | $23 |
| Idorsia Pharmaceuticals US Inc | 1 | $23 |
| Almatica Pharma LLC | 1 | $15 |
How this compares
$3,983 in reported general payments places this provider in the 80th percentile of 2,238 psychiatry providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ConcertaMethylphenidate Hcl | 13 | $10,331 |
| Bupropion XlBupropion Hcl | 41 | $402 |
| Escitalopram Oxalate | 17 | $254 |
| Duloxetine Hcl | 23 | $214 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 13 | $137 |
| Trazodone Hcl | 17 | $126 |
| Quetiapine Fumarate | 11 | $51 |
| Clonazepam | 13 | $33 |
| Zolpidem Tartrate | 12 | $29 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonConcerta | $175 | $10,33113 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,238 psychiatry providers in Texas.
Other psychiatry in Allen
- Scott BartleyDallas$42.7M
- David BrownAustin$15.8M
- Rajinder ShiwachDesoto$15.4M
- Darin OkudaDallas$14.7M
- Jason MensahBeaumont$10.3M
- Michael DowningDallas$7.6M
- Rakesh JainLake Jackson$7.2M
- Suresh SureddiPlano$5.9M
- Marshall LucasThe Woodlands$4.8M
- Sejal MehtaPlano$3.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.